Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

TCR alpha/beta/CD19-depleted allogeneic hematopoietic progenitor cells

A preparation of hematopoietic progenitor cells (HPCs) from a haploidentical donor that have been depleted of T-cell receptor (TCR) alpha and beta (TCRa/b+) as well as CD19-positive (CD19+) cells, that can potentially be used for immune reconstitution purposes. The TCR alpha/beta/CD19-depleted HPCs contain high amounts of natural killer (NK) cells, gamma/delta T cells, CD34+ stem cells, monocytes, and dendritic cells (DCs), while devoid of alpha/beta T cells and CD19-positive B cells. The TCR alpha/beta/CD19-depleted HPCs are used for allogeneic hematopoietic cell transplantation (HCT) and may allow for rapid and sustained engraftment, rapid immune reconstitution, and may prevent or reduce graft-versus-host disease (GvHD).
Synonym:allogeneic alpha, beta TCR/CD19-depleted HPCs
allogeneic TCRab/CD19-depleted hematopoietic stem cells
TCR alpha/beta/CD19-depleted HPCs
TCR alpha/beta+/CD19+ depleted ematopoietic progenitor cells
TCR alpha/beta+/CD19+ depleted HPCs
TCRab-/CD19-depleted allogeneic hematopoietic progenitor cells
TCRab-/CD19-depleted hematopoietic progenitor cells
TCRab+/CD19+-depleted haploidentical donor HPCs
Search NCI's Drug Dictionary